Latent Tuberculosis Therapy Outcomes in Dialysis Patients: A Retrospective Cohort

被引:9
作者
Chiang, Leslie Y. [1 ,2 ]
Baumann, Brett [3 ]
Romanowski, Kamila [1 ,2 ,3 ]
Kumar, Divjot [3 ]
Campbell, Jonathon R. [4 ]
Djurdjev, Ognjenka [2 ,5 ]
Morshed, Muhammad [2 ,3 ,6 ]
Sekirov, Inna [2 ,3 ,6 ]
Cook, Victoria J. [1 ,2 ,3 ]
Levin, Adeera [2 ,3 ,5 ]
Johnston, James C. [1 ,2 ,3 ]
机构
[1] British Columbia Ctr Dis Control, Vancouver, BC, Canada
[2] Prov Hlth Serv Author, Vancouver, BC, Canada
[3] Univ British Columbia, Vancouver, BC, Canada
[4] McGill Univ, Montreal, PQ, Canada
[5] British Columbia Renal, Vancouver, BC, Canada
[6] British Columbia Ctr Dis Control Publ Hlth Lab, Vancouver, BC, Canada
关键词
CHRONIC KIDNEY-DISEASE; INFECTION; TRIAL;
D O I
10.1053/j.ajkd.2020.06.017
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Rationale & Objectives: Maintenance dialysis patients are at an increased risk for active tuberculosis (TB). In 2012, British Columbia, Canada, began systematically screening maintenance dialysis patients for latent TB infection (LTBI) and treating people with evidence of LTBI when appropriate. We examined LTBI treatment outcomes and compared treatment outcomes before and after rollout of the systematic screening program. Study Design: Retrospective cohort study. Setting & Participants: The study comprised 365 people in British Columbia, Canada, initiating at least 90 days of dialysis from January 1, 2001, to May 31, 2017, and starting LTBI therapy: 290 (79.5%) people in the recent cohort and 75 (20.5%) in the historical cohort. People starting LTBI therapy from January 1, 2012, onward were classified as the recent cohort, whereas people starting LTBI therapy before January 1, 2012, were classified as the historical cohort. Exposure: Systematic LTBI screening and therapy. Outcomes: Proportion of people who experience grade 3 to 5 adverse events (AEs) or any grade rash and end-of-treatment outcomes. Analytical Approach: Outcomes were reported using descriptive statistics. 2-sample test of proportions using.2 distribution was used to test for statistical significance between the recent and historical cohorts. Results: 298 (81.6%) people successfully completed LTBI therapy. The proportion of people experiencing a grade 3 to 4 AE or any grade rash was 21.1%. Most AEs were related to gastrointestinal events, general malaise, or pruritus that resulted in regimen changes. 2 (0.5%) people were hospitalized for AEs related to LTBI therapy. No significant difference was found between the recent and historical cohorts in all outcomes of interest. No grade 5 AEs (deaths) were attributed to LTBI therapy. Limitations: Retrospective data and generalizability outside low-TB-burden settings. Conclusions: Our findings suggest that a high proportion of people receiving maintenance dialysis can complete LTBI therapy. The rate of grade 3 to 4 AEs was high and associated with frequent medication changes during therapy. LTBI therapy in maintenance dialysis may be safe but requires close monitoring.
引用
收藏
页码:696 / 703
页数:8
相关论文
共 22 条
  • [11] Aspects of immune dysfunction in end-stage renal disease
    Kato, Sawako
    Chmielewski, Michal
    Honda, Hirokazu
    Pecoits-Filho, Roberto
    Matsuo, Seiichi
    Yuzawa, Yukio
    Tranaeus, Anders
    Stenvinkel, Peter
    Lindholm, Bengt
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (05): : 1526 - 1533
  • [12] Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization
    Keith, DS
    Nichols, GA
    Gullion, CM
    Brown, JB
    Smith, DH
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (06) : 659 - 663
  • [13] LaFreniere M, 2019, Can Commun Dis Rep, V45, P67, DOI 10.14745/ccdr.v45i23a04
  • [14] Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events
    Lin, Shang-Yi
    Chiu, Yi-Wen
    Lu, Po-Liang
    Hwang, Shang-Jyh
    Chen, Tun-Chieh
    Hsieh, Min-Han
    Chen, Yen-Hsu
    [J]. JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2019, 52 (01) : 158 - 162
  • [15] Barriers to treatment adherence for individuals with latent tuberculosis infection: A systematic search and narrative synthesis of the literature
    Liu, Yisi
    Birch, Stephen
    Newbold, K. Bruce
    Essue, Beverley M.
    [J]. INTERNATIONAL JOURNAL OF HEALTH PLANNING AND MANAGEMENT, 2018, 33 (02) : E416 - E433
  • [16] Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults
    Menzies, D.
    Adjobimey, M.
    Ruslami, R.
    Trajman, A.
    Sow, O.
    Kim, H.
    Baah, J. Obeng
    Marks, G. B.
    Long, R.
    Hoeppner, V.
    Elwood, K.
    Al-Jahdali, H.
    Gninafon, M.
    Apriani, L.
    Koesoemadinata, R. C.
    Kritski, A.
    Rolla, V.
    Bah, B.
    Camara, A.
    Boakye, I.
    Cook, V. J.
    Goldberg, H.
    Valiquette, C.
    Hornby, K.
    Dion, M. -J.
    Li, P. -Z.
    Hill, P. C.
    Schwartzman, K.
    Benedetti, A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (05) : 440 - 453
  • [17] Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease
    Milburn, Heather
    Ashman, Neil
    Davies, Peter
    Doffman, Sarah
    Drobniewski, Francis
    Khoo, Saye
    Ormerod, Peter
    Ostermann, Marlies
    Snelson, Catherine
    [J]. THORAX, 2010, 65 (06) : 559 - 570
  • [18] Tuberculosis and chronic kidney disease: an emerging global syndemic
    Romanowski, Kamila
    Clark, Edward G.
    Levin, Adeera
    Cook, Victoria J.
    Johnston, James C.
    [J]. KIDNEY INTERNATIONAL, 2016, 90 (01) : 34 - 40
  • [19] An official ATS statement: Hepatotoxicity of antituberculosis therapy
    Saukkonen, Jussi J.
    Cohn, David L.
    Jasmer, Robert M.
    Schenker, Steven
    Jereb, John A.
    Nolan, Charles M.
    Peloquin, Charles A.
    Gordin, Fred M.
    Nunes, David
    Strader, Dorothy B.
    Bernardo, John
    Venkataramanan, Raman
    Sterling, Timothy R.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 174 (08) : 935 - 952
  • [20] Adverse events associated with treatment of latent tuberculosis in the general population
    Smith, Benjamin M.
    Schwartzman, Kevin
    Bartlett, Gillian
    Menzies, Dick
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2011, 183 (03) : E173 - E179